OBJECTIVE: To evaluate the therapeutic effects of recombinant Exendin-4 and double-stranded adeno-associated virus (Exendin-4/dsAAV) on SD @entity35 with type 2 @entity6 (T2DM) through injecting it into submandibular gland (SG).    METHODS: The Exendin-4/dsAAV was injected into submandibular gland of @entity6 @entity35 . The insulin and a-amylase were detected by real-time PCR at the 2nd, 4th and 8th weeks. The immunohistochemisty was used to detect the insulin contents in SG at the 8th week. The concentration of blood @entity413 and levels of insulin secretion were detected after pancreatectomy.    RESULTS: The SG gland was bigger in Exendin-4/dsAAV group than that in the control group, but the changes in a-amylase were not significant. The Exendin-4 and insulin gene expression was increased in the Exendin-4/dsAAV group (P<0.05). The Exendin-4 and insulin were positive in the SG. The blood @entity413 was lower and insulin concentration was higher in the Exendin-4/dsAAV group than those in the control group after pancreatectomy (P<0.05), and the insulin content was also increased in the dsAAV groups.    CONCLUSION: Continuous expression of Exendin-4 in SG may improve @entity413 control and insulin secretion in T2DM @entity35 through inducing expression of insulin.

[Injection of submandibular gland with recombinant Exendin-4 and adeno-associated virus for the treatment of @entity6 XXXX ].

@entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']
@entity35 :: (10116,Species) :: ['rats']
